Article
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
Antimicrobial agents and chemotherapy - 18 Oct 2021
Salaam-Dreyer Zubeida, Streicher Elizabeth M, Sirgel Frederick A, Menardo Fabrizio, Borrell Sonia, Reinhard Miriam, Doetsch Anna, Cudahy Patrick G T, Mohr-Holland Erika, Daniels Johnny, Dippenaar Anzaan, Nicol Mark P, Gagneux Sebastien, Warren Robin M, Cox Helen
Abstract excerpt
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aimed to compare RMR-TB with multidrug-resistant TB (MDR-TB) in a setting with high TB, RR-TB, and HIV burdens. Patient-level clinical data and stored RR Mycobacterium tuberculosis isolates from 2008 to 2017 with available...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
